How early is it possible to detect and to treat schizophrenia?;Wie früh kann eine schizophrenie erkannt und behandelt werden?

Nervenheilkunde

Volumn 25, Issue 5, 2006, Pages 351-358

  Vasic, Nenad ^a   Wolf, R C ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Early intervention; Prodrome; Schizophrenia; Untreated psychosis

Indexed keywords

DISEASE COURSE; EVIDENCE BASED PRACTICE; HEALTH ECONOMICS; HOSPITAL COST; HUMAN; PATIENT CARE; REVIEW; SCHIZOPHRENIA;

EID: 33750837899     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626470     Document Type: Review

References (77)

1. Amminger GP, Edwards J, Brewer WJ, Harrigan S, McGorry PD. Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophr Res 2002; 54: 223-30.
2. Birchwood M, McGorry P, Jackson H. Early intervention in schizophrenia. Br J Psychiatry 1997; 170: 2-5.
3. Browne S, Clarke M, Gervin M, Waddington JL, Larkin C, O'Callaghan E. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry 2000; 176: 173-6.
4. Cannon M, Clarke MC. Risk for schizophrenia-broadening the concepts, pushing back the boundaries. Schizophr Res 2005; 79: 5-13.
5. Cannon M, Walsh E, Hollis C, Kargin M, Taylor E, Murray RM, Jones PB. Predictors of later schizophrenia and affective psychosis among attendees at a child psychiatry department. Br J Psychiatry 2001; 178: 420-6.
6. Cannon TD, Huttunen MO, Dahlstrom M, Larmo I, Rasanen P, Juriloo A. Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am J Psychiatry 2002; 159: 1230-2.
7. Carbone S, Harrigan S, McGorry PD, Curry C, Elkins K. Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatr Scand 1999; 100: 96-104.
8. Clade H. Versorgungsforschung: Fallbeispiel Schizophrenie - Hohe soziale Kosten. Deutsches Ärzteblatt 2003; 8: 353.
9. Cornblayt B, Lencz T, Corell C, Author A, Smith C. Treating the prodrome: naturalistic findings from the RAP program. Acta Psychiatr Scand 2002; 106 (suppl): 44.
10. Comblatt BA. The New York high risk project to the Hillside recognition and prevention (RAP) program. Am J Med Genet 2002; 114: 956-66.
11. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001; 51: 31-8.
12. Craig TJ, Bromet EJ, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 2000; 157: 60-6.
13. DeGrazia D. Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia. Schizophr Res 2001; 51: 77-86.
14. Deister A.SM. Verlauf schizophrener Psychosen. In: M. S (Hrsg). Schizophrenie - Pathogenese, Diagnostik und Therapie, 1. ed, Vol Bremen: UNIMED Verlag AG 2002; 79-90.
15. DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998; 59 Suppl 19: 9-17.
16. Edwards J, Maude D, McGorry PD, Harrigan SM, Cocks JT. Prolonged recovery in first-episode psychosis. Br J Psychiatry Suppl 1998; 172: 107-16.
17. Falloon IR, Kydd RR, Coverdale JH, Laidlaw TM. Early detection and intervention for initial episodes of schizophrenia. Schizophr Bull 1996; 22: 271-82.
18. Gaebel W, Moeller HJ. Kompetenznetz Schizophrenie: http://www. kompetenznetz-schizophre nie.de/rdkns/index.htm 2005.
19. Gottesman H. Schizophrenia epigenesis: past, present, and future. Acta Psychiatr Scand Suppl 1994; 384: 26-33.
20. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24.
21. Haas GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res 1998; 32: 151-9.
22. Häfner H. Was ist Schizophrenie? In: Was ist Schizophrenie? Stuttgart Jena New York: Fischer Verlag 1995.
23. Häfner H adHW. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 1999; 249: 14-26.
24. Hafner H, Maurer K, Loffler W, Riecher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993; 162: 80-6.
25. Hanssen M, Bak M, Bijl R, Vollebergh W, van Os J. The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol 2005; 44: 181-91.
26. Harris MG, Henry LP, Harrigan SM, Purcell R, Schwarte OS, Farrelly SE, Prosser AL, Jackson HJ, McGorry PD. The relationship between duration of untreated psychosis and outcome: An eight-year prospective study. Schizophr Res 2005.
27. Heinssen RK, Perkins DO, Appelbaum PS, Fenton WS. Informed Consent in Early Psychosis Research: National Institute of Mental Health workshop, November 15, 2000. Schizophr Bull 2001; 27: 571-83.
28. Ho BC, Alicata D, Mola C, Andreasen NC. Hippocampus volume and treatment delays in first-episode schizophrenia. Am J Psychiatry 2005; 162: 1527-9.
29. Ho BC, Alicata D, Ward J, Moser DJ, O'Leary DS, Arndt S, Andreasen NC. Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am J Psychiatry 2003; 160: 142-8.
30. Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry 2000; 157: 808-15.
31. Hoff P. SM. Psychotische Erkrankungen: Die psychiatriehistorische Perspektive. In: Schizophrenie - Pathogenese, Diagnostik und Therapie, 1. ed, Vol Bremen: UNI-MED Verlag AG 2002; 20-34.
32. Holzer L, Halfen O, Laget J. Intervention in adolescent psychosis risk. J Am Acad Child Adolesc Psychiatry 2005; 44: 512.
33. Huber G. Die Schizophrenien. In: Psychiatrie. Lehrbuch für Studierende und Ärzte., 5. ed, Vol Stuttgart, New York: Schattauer 1994; 252-386.
34. Huber G, Gross G, Schuttler R. Schizophrenia. Clinical course and social psychiatric long term examinations of schizophrenic patients hospitalized in Bonn from 1945-1959. Monogr Gesamtgeb Psychiatr Psychiatry Ser 1979; 21: 1-399.
35. Jablensky A. The 100-year epidemiology of schizophrenia. Schizophr Res 1997; 28: 111-25.
36. Keshavan MS. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res 1999; 33: 513-21.
37. Keshavan MS, Haas G, Miewald J, Montrose DM, Reddy R, Schooler NR, Sweeney JA. Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses. Schizophr Bull 2003; 29: 757-69.
38. Kissling W, Seemann U, Müller P, Rüther E, Trenckmann U, Uber A, Glaser P, Glaser Th, Mast O, Schmidt D. Die indirekten und direkten Kosten der Schizophrenie. Fortschr Neurol Psychiat 1999; 67: 29-36.
39. Klosterkötter J, Schultze-Lutter F. Is there a primary prevention of schizophrenic psychosis?. Fortschr Neurol Psychiat 2001; 69: 104-12.
40. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004; 184: 509-16.
41. Larsen TK, Johannessen JO, Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis. Pathways to care. Br J Psychiatry Suppl 1998; 172: 45-52.
42. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001; 50: 884-97.
43. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000; 18: 106-24.
44. Linszen D, Lenior M, De Haan L, Dingemans P, Gersons B. Early intervention, untreated psychosis and the course of early schizophrenia. Br J Psychiatry Suppl 1998; 172: 84-9.
45. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-8.
46. Machleidt W, Lamprecht F, Rohde-Dachser C. Rose H. K. Schizophrene Störungen In: Psychiatrie, Psychosomatik und Psychotherapie, 6 ed, Vol Stuttgart New York: Georg Thieme Verlag 1999.
47. Malla AK, Norman RM, Voruganti LP. Improving outcome in schizophrenia: the case for early intervention. Cmaj 1999; 160: 843-6.
48. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996; 22: 201-22.
49. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996; 22: 305-26.
50. McGorry PD, Singh BS. Schizophrenia: risk and possibility, in: Raphael B, Burrows, G.D. (Hrsg). Handbook of Studies on Preventive Psychiatry-Amsterdam: Elsevier 1995; 491-514.
51. McGorry PD, Yung AR, Phillips LJ. The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 2003; 29: 771-90.
52. McGorry PD et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms Arch Gen Psychiatry 2002; 59: 921-8.
53. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 2: 13.
54. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495-506.
55. Milev P, Ho BC, Arndt S, Nopoulos P, Andreasen NC. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up. Biol Psychiatry 2003; 54: 608-15.
56. Miller TJ et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res 2003; 61: 19-30.
57. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med 2001; 31: 381-400.
58. Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust N Z J Psychiatry 2000; 34 Suppl: S164-9.
59. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 2000; 57: 1053-8.
60. Remington G, Shammi C. The use of pharmacotherapy in the prodrome of schizophrenia. CNS Spectr 2004; 9: 579-86.
61. Robinson D et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-7.
62. Rössler W. SJ, Knapp M. Die Kosten der Schizophrenie. Fortschr Neurol Psychiat 1998; 66: 496-504.
63. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 2003; 36 Suppl 3: S162-7.
64. Ruhrmann S et al. Functional disability in the prodromal phase of psychosis. Eur Psychiatry 2004; 19: S11.
65. Rund BR, Melle I, Friis S, Larsen TK, Midboe LJ, Opjordsmoen S, Simonsen E, Vaglum P, McGlashan T. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry 2004; 161: 466-72.
66. Schuepbach FJ, Hill SK, Sanders RD, Hell D, Keshavan MS, Sweeney JA. Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naive first episode schizophrenia: a 2-year follow up. Schizophr Bull 2004; 30: 837-48.
67. Scully PJ, Coakley G, Kinsella A, Waddington JL. Executive (frontal) dysfunction and negative symptoms in schizophrenia: apparent gender differences in 'static' v. 'progressive' profiles. Br J Psychiatry 1997; 171: 154-8.
68. Scully PJ, Coakley G, Kinsella A, Waddington JL. Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychol Med 1997; 27: 1303-10.
69. Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry 1996; 153: 519-25.
70. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508-16.
71. Tsuang MT, Stone WS, Seidman LJ, Faraone SV, Zimmet S, Wojcik J, Kelleher JP, Green AI. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biol Psychiatry 1999; 45: 1412-8.
72. Waddington JL, Youssef HA, Kinsella A. Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychol Med 1995; 25: 849-57.
73. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998; 24: 75-85.
74. Woods SW et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003; 54: 453-64.
75. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325-51.
76. Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychol Med 1997; 27: 261-8.
77. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res 2003; 60: 21-32.